AIM ImmunoTech Inc.

Last updated September 27, 2026

Organization details

Legal name
AIM ImmunoTech Inc.
Former names
Hemispherx Biopharma Inc
Ownership
Public
Status
Active
Sector (GICS)
Health Care
SIC code
2836 — Biological Products, (No Diagnostic Substances)
Jurisdiction of incorporation
Delaware
Headquarters city
Ocala
Headquarters state / province
Florida
Headquarters country
United States
Fiscal year end
December
Ticker symbol
AIM
Primary stock exchange
NYSE American

Identifiers

SEC CIK
0000946644
EIN
52-0845822

Board of directors

Chief executives

Thomas K. Equels · CEO & President
Dates unknown

Director election results

Annual meeting of December 17, 2024. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.

Insider trades

All notable trades →

From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.

Bought, last 12 months
$44,498
11 purchases by 1 insider
Sold, last 12 months
$0
0 sales by 0 insiders
Date Insider Transaction Shares Price Value
Nov 11, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +35,000 $0.15 $5,215
Nov 10, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +39,000 $0.14 $5,382
Nov 9, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +31,298 $0.16 $5,070
Nov 6, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +20,299 $0.16 $3,167
Nov 6, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +12,751 $0.16 $2,015
Oct 23, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +31,675 $0.16 $5,068
Oct 22, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +31,250 $0.16 $5,094
Sep 17, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +24,000 $0.21 $5,040
Sep 16, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +11,000 $0.21 $2,310
Sep 15, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +22,000 $0.22 $4,840
Sep 14, 2026 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +5,900 $0.22 $1,298
Mar 12, 2026 Thomas K. Equels Director, Officer (CEO & President) Derivative conversion +25,000 — —
Mar 12, 2026 David I. Chemerow Director Derivative conversion +25,000 — —
Feb 5, 2026 David I. Chemerow Director Grant or award +2,800 $1.23 $3,444
Jun 13, 2025 Thomas K. Equels Director, Officer (CEO & President) Open-market purchase +107 $7.70 $824

Organizations in the same sector, closest in location and size first.

Questions about AIM ImmunoTech Inc.

Who is the CEO of AIM ImmunoTech Inc.?

Thomas K. Equels is AIM ImmunoTech Inc.'s CEO & President.

How many directors are on AIM ImmunoTech Inc.'s board?

AIM ImmunoTech Inc.'s board has 6 directors: David I. Chemerow, Nancy Bryan, Stewart Appelrouth, Ted D. Kellner, Thomas K. Equels and William M. Mitchell.

Are AIM ImmunoTech Inc. insiders buying or selling shares?

Over the last 12 months, AIM ImmunoTech Inc. insiders bought $44,498 of shares in 11 purchases and made no open-market sales on the open market, as reported to the SEC on Forms 4 and 5.

Embed this board on your site

Paste this where the board should appear. It always shows the current directors and links back here.

<div data-bod-board="aim-immunotech-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>

Reviews (0)

Sign in to write a review.

No reviews yet. Be the first to write one.

We use cookies to run this site and, with your permission, to measure traffic and support the affiliate links that help fund it.